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Conclusions: The presence of intravenous contrast agent does not 
significantly affect the dose calculation in CT-based 3D-CRT planning 
of pelvis and head-and-neck.  
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Purpose/Objective: The dosimetric aspects of radiotherapy treatment 
plan quality are evaluated with isodoses and dose volume histogram 
(DVH) values. Usually, the reporting consists in some particular values 
for target volumes (TV) and organs at risk (OAR). However, due to the 
complexity of the IMRT dose distributions, given a patient and 
treatment goals, several operators produce their own optimal plan 
depending on their experience and their tradeoffs between TV and 
OAR DVH endpoints. The aim of this study was (1) to evaluate the 
operator variability in our institution and (2) to improve the relevancy 
of the DVH endpoints. The study focused on Tomotherapy planning for 
head and neck cases. 
Materials and Methods: Ten patients with bilateral lymphatic node 
irradiation were selected from our database. Prescribed doses for 
planning target volumes PTV(tumor) and lymphatic nodes PTV(nodes) 
were 70Gy and 56Gy in 35 fractions respectively. For each patient, 
seven physicists of our department produced their own plan based on 
the same set of contours and the same treatment goals. For plan 
validation, DVH endpoints were related to the following organs: GTV 
(D98%), PTV(tumor) (D98%, D2%), PTV(nodes) D(98%), spinal cord 
(D2%), parotid glands (Dmean, V45Gy, V30Gy), larynx (V50Gy), oral 
cavity(V50Gy). The inter-operator variability was studied by 
comparing the DVH values. Three groups of values were evaluated (i) 
PTVs, (ii) principal OARs for which the respect of endpoints is 
mandatory and (iii) secondary OARs for which the respect of endpoints 
improves the patient quality of life. 
Results: Physicists had an experience with Tomotherapy planning 
software ranging from 1 to 5 years. 70 plans were generated and were 
evaluated by a single physician. For all patients, all plans were 
clinically acceptable despite some discrepancies. For group (i), the 
main difference concerned D98% for PTV(tumor) and PTV(nodes) that 
were lower for two planners. For group (ii), the D2% to the spinal cord 
never exceeded 38Gy. Large differences were observed but they were 
considered minor by the physician. For group (iii), experience and 
tradeoffs of the planners yielded different dosimetric results, 
especially in the larynx and in the ipsilateral parotid gland. This organ 
sparing can lead to an slight undercoverage of the PTV(tumor). 
Whatever the group, differences were particularly observed for the 
first patients studied, but were reduced during the study. 
Conclusions: This work showed inter-operator variability in 
Tomotherapy planning for head and neck cases. However, all plans 
were acceptable by the physician. This comparison allowed to better 
define the priority of the endpoints to evaluate the quality of a plan 
and to narrow the variability over the study.  
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Purpose/Objective: Volumetric-modulated arc therapy (VMAT) is a 
relatively new treatment modality, in which gantry rotation and 
speed, dose-rate and multileaf collimator (MLC) leaves motion vary 
simultaneously. The aim of the study was to compare conventional 
intensity modulated radiation therapy (IMRT) with VMAT plans for 
prostate cancers. 
Materials and Methods: Ten randomly selected patients with prostate 
cancer were included for the present study. Contours for each pts 
were drawn using our clinical protocol. For each patient, three plans 
were generated for treatment modalities using a 80 leaves MLC with 
the leaves of 10 mm (MLCi2 Elekta Synergy). All IMRT and VMAT plans 
were calculated for 6MV photons. IMRT plan were generated using 
Oncentra Master Plan (v 3.3), whereas VMAT plans were performed 
with Monaco (v 3.2). The dose prescription was 76 Gy in 38 fractions 
to the target volume with respect the dose volume criteria for the 
organ at risk (OAR) complied with QUANTEC recommendation. Dose-
volume parameters of the plans were evaluated according to Rapport 
ICRU No 81.  
Results: All techniques: IMRT as well as VMAT result in treatment 
plans which comply with our current applied clinical protocol. From 
the DVH data, target coverage achieved similar results for IMRT and 
VMAT (table1): V95% - 99,3±0,7% and 99,2±0,7% for IMRT and VMAT, 
respectively. The average dose were 102,5±3,2% for IMRT and 
102,4±3,3% for VMAT. For OAR all planning objectives were largely 
met. VMAT plans were superior for rectum in all dose-volume 
constraints (p<0.05). Similar results were achieved in dose-volume 
constraints for bladder. VMAT leads to the average reduction of about 
6 Gy for the mean dose for rectum and of about 11 Gy for mean dose 
for bladder comparing to IMRT. There were no statistical differences 
between IMRT and VMAT in mean and dose-volume parameters for 
femurs. The average MU were 452±.81,7, and 510.9±.50,6for IMRT and 
VMAT, respectively. 
Conclusions: VMAT achieved similar target coverage to IMRT plans for 
prostate cancer pts. It provided a better OAR sparing due to reduction 
of high-dose-receiving area of healthy tissue. Further studies are 
indicated to evaluated the VMAT impact on quality of life of prostate 
cancer pts during and after the therapy. 
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